NuVasive brings together surgeons, hospital executives, clinical leaders and policy experts to discuss spine care; former NFL Pro Bowl quarterback Archie Manning delivers keynote address
SAN DIEGO – October 4, 2017 – NuVasive, Inc. (NASDAQ: NUVA), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, is hosting the 2nd Annual Spine Summit in San Diego on October 4 – 6, 2017. This unique educational event brings together hospital executives, healthcare leaders, industry visionaries and surgeons to discuss the future of spine care and build out solutions to deliver high-quality care for patients. The opening keynote address features newly named NuVasive spokesman Archie Manning.
The Spine Summit features interactive sessions on topics that include employer-payer collaboration, service line partnerships for spine, healthcare policy, and the clinical and economic value of spine diagnostics. Speakers include industry leaders from health systems, ambulatory surgical centers and clinics around the country, and government policy experts from Washington D.C. These experts come from some of the leading healthcare organizations including United Healthcare, Aon Hewitt, Virginia Mason Medical Center and The CORE Institute.
“As the largest pure play spine technology company in the world and developer of market-leading innovation, no one is better positioned to bring together industry leaders to shape and improve the future of spine,” said Gregory T. Lucier, chairman and chief executive officer of NuVasive. “Our goal in hosting the Spine Summit is to create the leading platform for discussion and collaboration between those who can better capture and measure outcomes while reducing healthcare costs to influence improvements in overall spine care.”
In addition to facilitating dialog among key spine industry influencers, NuVasive is honored that Manning will share his personal story on how the company’s innovative spine procedure changed his life. Manning, a College Football Hall of Fame inductee, National Football League (NFL) inductee and former NFL Pro Bowl quarterback, suffered severe nerve compression caused by two collapsed discs on the left side in his lumbar spine. His surgeon, James Woodall Jr., MD, Mississippi Sports Medicine and Orthopaedic Center, determined that the NuVasive XLIF® procedure was the optimal solution to restore height and stability to the collapsed disc space. XLIF is the leading lateral spine procedure, supported by over 10 years of clinical evidence.
Basketball legend and NuVasive ambassador Bill Walton will close the Spine Summit by sharing his story about how the company’s XLIF procedure relieved him from life-threatening back pain.
NuVasive, Inc. (NASDAQ: NUVA) is transforming spine surgery and beyond with minimally invasive, procedurally-integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company’s portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With $962 million in revenues (2016), NuVasive has an approximate 2,300 person workforce in more than 40 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA™ platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
# # #